JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balzarini, J.
Right arrow Articles by De Clercq, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balzarini, J.
Right arrow Articles by De Clercq, E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J. Biol. Chem., Vol. 267, Issue 17, 11831-11838, Jun, 1992

Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T)

J Balzarini, MJ Perez-Perez, A San-Felix, MJ Camarasa, IC Bathurst, PJ Barr and E De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

[2',5'-Bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro- 5"-(4"-amino-1",2"-oxathiole-2", 2"-dioxide)thymine (TSAO-T) is a representative of a novel class of nucleoside analogues that are endowed with a potent and specific activity against human immunodeficiency virus (HIV) type 1 and are targeted at the HIV-1 reverse transcriptase (RT). Inhibition of HIV-1 RT by TSAO-T was reversible and noncompetitive with respect to dGTP as the substrate and poly(C).oligo(dG) as the template/primer. In contrast with the nonnucleoside derivatives tetrahydroimidazo-[4,5,1-jk][1,4]- benzodiazepin-2(1H)-thione (TIBO) (R-82150), nevirapine (BI-RG-587) and the HEPT derivative I-HEPU-SdM, TSAO-T was not inhibitory to HIV-1 RT in the presence of other homopolymeric template/primers. It did not interfere with the DNA-dependent DNA polymerase function of HIV-1 RT, HIV-2 RT, herpes simplex virus type 1 DNA polymerase, or Taq polymerase. However, TSAO-T proved inhibitory to the HIV-1 RT reaction primed by Escherichia coli 16S/23S rRNA, irrespective of the nature of the radiolabeled 2'-deoxynucleotide 5'-triphosphate (dNTP) used. TSAO-T does not act as a DNA chain terminator. It interacts with HIV-1 RT at a nonsubstrate (dNTP)-binding site.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
D. Jochmans, J. Deval, B. Kesteleyn, H. Van Marck, E. Bettens, I. De Baere, P. Dehertogh, T. Ivens, M. Van Ginderen, B. Van Schoubroeck, et al.
Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action
J. Virol., December 15, 2006; 80(24): 12283 - 12292.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Auwerx, F. Rodriguez-Barrios, F. Ceccherini-Silberstein, A. San-Felix, S. Velazquez, E. De Clercq, M.-J. Camarasa, C.-F. Perno, F. Gago, and J. Balzarini
The Role of Thr139 in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Sensitivity to (+)-Calanolide A
Mol. Pharmacol., September 1, 2005; 68(3): 652 - 659.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. Auwerx, M. Stevens, A. R. Van Rompay, L. E. Bird, J. Ren, E. De Clercq, B. Oberg, D. K. Stammers, A. Karlsson, and J. Balzarini
The Phenylmethylthiazolylthiourea Nonnucleoside Reverse Transcriptase (RT) Inhibitor MSK-076 Selects for a Resistance Mutation in the Active Site of Human Immunodeficiency Virus Type 2 RT
J. Virol., July 15, 2004; 78(14): 7427 - 7437.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. Van Herrewege, J. Michiels, J. Van Roey, K. Fransen, L. Kestens, J. Balzarini, P. Lewi, G. Vanham, and P. Janssen
In Vitro Evaluation of Nonnucleoside Reverse Transcriptase Inhibitors UC-781 and TMC120-R147681 as Human Immunodeficiency Virus Microbicides
Antimicrob. Agents Chemother., January 1, 2004; 48(1): 337 - 339.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Auwerx, R. Esnouf, E. De Clercq, and J. Balzarini
Susceptibility of Feline Immunodeficiency Virus/Human Immunodeficiency Virus Type 1 Reverse Transcriptase Chimeras to Non-Nucleoside RT Inhibitors
Mol. Pharmacol., January 1, 2004; 65(1): 244 - 251.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Odriozola, C. Cruchaga, M. Andreola, V. Dolle, C. H. Nguyen, L. Tarrago-Litvak, A. Perez-Mediavilla, and J. J. Martinez-Irujo
Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase Inhibit Phosphorolysis and Resensitize the 3'-Azido-3'-deoxythymidine (AZT)-resistant Polymerase to AZT-5'-triphosphate
J. Biol. Chem., October 24, 2003; 278(43): 42710 - 42716.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Stevens, C. Pannecouque, E. De Clercq, and J. Balzarini
Novel Human Immunodeficiency Virus (HIV) Inhibitors That Have a Dual Mode of Anti-HIV Action
Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3109 - 3116.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Stevens, C. Pannecouque, E. De Clercq, and J. Balzarini
Inhibition of Human Immunodeficiency Virus by a New Class of Pyridine Oxide Derivatives
Antimicrob. Agents Chemother., September 1, 2003; 47(9): 2951 - 2957.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Auwerx, T. W. North, B. D. Preston, G. J. Klarmann, E. De Clercq, and J. Balzarini
Chimeric Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Reverse Transcriptases: Role of the Subunits in Resistance/Sensitivity to Non-Nucleoside Reverse Transcriptase Inhibitors
Mol. Pharmacol., February 1, 2002; 61(2): 400 - 406.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H. Pelemans, R. Esnouf, E. De Clercq, and J. Balzarini
Mutational Analysis of Trp-229 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Identifies This Amino Acid Residue as a Prime Target for the Rational Design of New Non-Nucleoside RT Inhibitors
Mol. Pharmacol., May 1, 2000; 57(5): 954 - 960.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
H. Pelemans, R. M. Esnouf, H. Jonckheere, E. De Clercq, and J. Balzarini
Mutational Analysis of Tyr-318 within the Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket of Human Immunodeficiency Virus Type I Reverse Transcriptase
J. Biol. Chem., December 18, 1998; 273(51): 34234 - 34239.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Balzarini, H. Pelemans, A. Karlsson, E. De Clercq, and J.-P. Kleim
Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors
PNAS, November 12, 1996; 93(23): 13152 - 13157.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1992 by the American Society for Biochemistry and Molecular Biology.